ZA200110071B - Recombinant platelet collagen receptor Glycoprotein VI and its pharmaceutical use. - Google Patents

Recombinant platelet collagen receptor Glycoprotein VI and its pharmaceutical use.

Info

Publication number
ZA200110071B
ZA200110071B ZA200110071A ZA200110071A ZA200110071B ZA 200110071 B ZA200110071 B ZA 200110071B ZA 200110071 A ZA200110071 A ZA 200110071A ZA 200110071 A ZA200110071 A ZA 200110071A ZA 200110071 B ZA200110071 B ZA 200110071B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical use
collagen receptor
recombinant platelet
receptor glycoprotein
platelet collagen
Prior art date
Application number
ZA200110071A
Other languages
English (en)
Inventor
Kenneth J Clemetson
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200110071(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200110071B publication Critical patent/ZA200110071B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/018—Platelets
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
ZA200110071A 1999-05-07 2001-12-06 Recombinant platelet collagen receptor Glycoprotein VI and its pharmaceutical use. ZA200110071B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99109094 1999-05-07

Publications (1)

Publication Number Publication Date
ZA200110071B true ZA200110071B (en) 2003-03-06

Family

ID=8238132

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200110071A ZA200110071B (en) 1999-05-07 2001-12-06 Recombinant platelet collagen receptor Glycoprotein VI and its pharmaceutical use.

Country Status (26)

Country Link
US (5) US7928066B1 (xx)
EP (3) EP1942186B1 (xx)
JP (2) JP5480457B2 (xx)
KR (1) KR100703592B1 (xx)
CN (1) CN1253569C (xx)
AR (1) AR023848A1 (xx)
AT (1) ATE393223T1 (xx)
AU (1) AU775952B2 (xx)
BR (1) BRPI0010325B1 (xx)
CA (1) CA2372515C (xx)
CY (2) CY1108190T1 (xx)
CZ (1) CZ302693B6 (xx)
DE (1) DE60038675T2 (xx)
DK (2) DK1177289T3 (xx)
ES (2) ES2534652T3 (xx)
HK (1) HK1045714B (xx)
HU (1) HUP0201049A2 (xx)
MX (1) MXPA01011274A (xx)
NO (1) NO333408B1 (xx)
PL (1) PL204449B1 (xx)
PT (2) PT2341141E (xx)
RU (1) RU2287580C2 (xx)
SI (1) SI1177289T1 (xx)
SK (1) SK15762001A3 (xx)
WO (1) WO2000068377A1 (xx)
ZA (1) ZA200110071B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK15762001A3 (sk) 1999-05-07 2002-04-04 Merck Patent Gmbh Rekombinantný doštičkový kolagénový receptor glykoproteínu VI a jeho farmaceutické použitie
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
EP1406929A2 (en) * 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusion proteins
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
DE102004017295A1 (de) * 2004-04-05 2005-11-03 Zlb Behring Gmbh Verbindungen, welche die Entfernung von Rezeptoren von Zelllmembranen bewirken oder verhindern, und Verfahren zu ihrem Nachweis
CN1964990B (zh) 2004-04-29 2012-12-12 大冢制药株式会社 糖蛋白ⅵ特异的抗体以及生产这些抗体的方法
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
RU2010121878A (ru) * 2007-10-31 2011-12-10 Оцука Фармасьютикал Ко., Лтд. (Jp) Применения ингибитора гликопротеина vi (gpvi)
EP2694709B1 (en) 2011-04-08 2016-09-14 Prognosys Biosciences, Inc. Peptide constructs and assay systems
EP3184544A1 (en) * 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT662088E (pt) 1993-07-01 2002-06-28 Merck Patent Gmbh Inibidor da agregacao de plaquetas estimulada por colagenio
AU701576B2 (en) * 1993-10-22 1999-02-04 Trigen Limited Platelet-derived growth factor analogues
AU5927398A (en) * 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Fc receptors and polypeptides
CA2250291A1 (en) * 1997-01-29 1998-07-30 Toray Industries Inc. Chimeric proteins, their heterodimer complexes, and platelet substitutes
SK15762001A3 (sk) 1999-05-07 2002-04-04 Merck Patent Gmbh Rekombinantný doštičkový kolagénový receptor glykoproteínu VI a jeho farmaceutické použitie
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1406929A2 (en) 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusion proteins
EP1538165A1 (en) 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4

Also Published As

Publication number Publication date
NO333408B1 (no) 2013-05-27
AU4555500A (en) 2000-11-21
CZ20013989A3 (cs) 2002-02-13
CN1350583A (zh) 2002-05-22
JP5554696B2 (ja) 2014-07-23
KR20010112951A (ko) 2001-12-22
HK1045714A1 (en) 2002-12-06
EP1177289B1 (en) 2008-04-23
CY1116336T1 (el) 2017-02-08
JP2011097948A (ja) 2011-05-19
CA2372515C (en) 2015-12-01
PL204449B1 (pl) 2010-01-29
DE60038675D1 (de) 2008-06-05
AR023848A1 (es) 2002-09-04
EP1942186A2 (en) 2008-07-09
DK1177289T3 (da) 2008-08-11
CZ302693B6 (cs) 2011-09-07
EP2341141B1 (en) 2015-01-14
PT1177289E (pt) 2008-06-30
US20160207976A1 (en) 2016-07-21
DK2341141T3 (en) 2015-04-20
KR100703592B1 (ko) 2007-04-05
EP1942186B1 (en) 2017-04-12
RU2287580C2 (ru) 2006-11-20
EP1177289A1 (en) 2002-02-06
HUP0201049A2 (hu) 2002-07-29
EP1942186A3 (en) 2008-10-08
NO20015420D0 (no) 2001-11-06
NO20015420L (no) 2002-01-03
ATE393223T1 (de) 2008-05-15
US7928066B1 (en) 2011-04-19
JP5480457B2 (ja) 2014-04-23
US20070172893A1 (en) 2007-07-26
DE60038675T2 (de) 2009-07-02
AU775952B2 (en) 2004-08-19
JP2003515313A (ja) 2003-05-07
MXPA01011274A (es) 2002-05-06
EP2341141A3 (en) 2012-03-28
SK15762001A3 (sk) 2002-04-04
WO2000068377A1 (en) 2000-11-16
US8198030B2 (en) 2012-06-12
EP2341141A2 (en) 2011-07-06
HK1045714B (zh) 2006-09-22
BRPI0010325B1 (pt) 2016-01-19
CY1108190T1 (el) 2014-02-12
SI1177289T1 (sl) 2008-08-31
US20070172480A1 (en) 2007-07-26
CN1253569C (zh) 2006-04-26
PT2341141E (pt) 2015-04-30
US20110237655A1 (en) 2011-09-29
US8278430B2 (en) 2012-10-02
PL351437A1 (en) 2003-04-22
ES2534652T3 (es) 2015-04-27
CA2372515A1 (en) 2000-11-16
ES2304347T3 (es) 2008-10-16
BR0010325A (pt) 2002-02-26

Similar Documents

Publication Publication Date Title
ZA200110071B (en) Recombinant platelet collagen receptor Glycoprotein VI and its pharmaceutical use.
HUP0302969A3 (en) Npyy5 antagonists, pharmaceutical compositions containing them and their use
IL181468A (en) E2 subunit vaccine comprising recombinant pestivirus e2 protein
HUP9801433A2 (hu) IIb/IIIa Glikoprotein antagonisták, ezek előállítása és alkalmazása, valamint ezeket tartalmazó gyógyászati készítmények
HUP0103265A3 (en) Cyclic prosaposin-derived peptides, pharmaceutical compositions comprising thereof and their use
ZA9711316B (en) Vitronectin receptor antagonists, their preparation and their use.
IL130229A0 (en) Novel human beta2 integrin alpha subunit
EP1229910A4 (en) integrin
EP1194151A4 (en) ANTAGONISTS OF THE INTEGRIN RECEPTORS
IL133686A0 (en) Glycoprotein hormone analogs, their preparation and use
IL135797A (en) Thrombin receptor antagonists and pharmaceutical compositions comprising them
HUP0204113A3 (en) Novel integrin receptor antagonists, pharmaceutical compositions containing them and their use
CZ2000522A3 (cs) Farmaceutický prostředek na bázi piperidinalkanolového antihistaminika a použití
HUP0500079A3 (en) Chemokine receptor antagonists, their use and pharmaceutical compositions containing them
HUP0201696A3 (en) Cyclic peptides, pharmaceutical compositions comprising thereof and their use
EP1239039A4 (en) NEW POLYPEPTIDE AND ENCODING DNA
HUP0202710A3 (en) Vitronectin receptor antagonists, pharmaceutical compositions containing them and their use
IL131266A0 (en) Peptides and pharmaceutical compositions comprising same
IL146146A0 (en) Integrin receptor antagonists
IL148446A0 (en) Iren protein, its preparation and use
EP1241257A4 (en) TACHYKININ-SIMILAR POLYPEPTIDES AND ITS APPLICATION
EP1223946A4 (en) HUMAN NEUROPEPTIDE RECEPTOR
GB9917165D0 (en) Polypeptides polynuclcotides and uses thereof
GB9924484D0 (en) Altered polypeptide aggregation
GB9801621D0 (en) Recombinant birA protein